Skip to content
Asston Pharmaceuticals logo

Asston Pharmaceuticals

544445 BSE
₹138.00

Close ·

View as Markdown
MCP
Close 4 Nov 2026 ₹138.00 +58.00 +72.5% 1Y
Start ₹80.00

Key Fundamentals

SMEElectrical EquipmentCapital Goods

Price-based figures at the close · TTM

ROCE
17.00%
Debt to Equity
0.13
EPS (TTM)
—
Book Value
₹60.96
Market Cap
—
P/E (TTM)
—
P/B
2.26
ROE
15.70%
Dividend Yield
0.00%
EBITDA
₹5.60 Cr
52W High
₹153.40
52W Low
₹60.00

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

46 Average

Data confidence 81/100

Category scores

Quality
55
Average
Returns, margins, earnings quality 22% weight
Valuation
30
Poor
Cheap vs sector & own history 24% weight
Growth
40
Weak
Sales & profit trajectory 9% weight
Financial Health
76
Strong
Solvency, leverage, coverage 9% weight
Momentum
99
Strong
Trend strength, vol-adjusted 12% weight
Ownership
18
Poor
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has reduced debt.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%

Weaknesses

6
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding has decreased over last quarter: -11.2%
  • Promoter holding is low: 39.5%
  • Earnings include an other income of Rs.6.07 Cr.
  • Company has high debtors of 524 days.
  • Working capital days have increased from 258 days to 434 days

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish2512
OscillatorsBullish153
Moving AveragesStrong Bullish109

Key readings

RSI (14)
65.70
Neutral
MACD (12,26,9)
12.28
Bullish
SMA (50)
110.68
Bullish
SMA (200)
87.40
Bullish

As of

Growth Rate

From the financial statements below. 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
3Y+57.33%
1Y+1.72%

Net profit

Net profit growth by window
3Y+53.98%
1Y+0.52%

Operating cash flow

Operating cash flow growth by window
3YOutflow widened by ₹9.86 Cr
1YOutflow widened by ₹10.15 Cr

Operating margin· change in pp

Operating margin growth by window
3Y−25.28 pp
1Y−23.77 pp

Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.

Revenue by year

Revenue by year, ₹ crore
Mar 2022₹9.60 Cr
Mar 2023₹6.54 Cr
Mar 2024₹16.03 Cr
Mar 2025₹25.04 Cr
Mar 2026₹25.47 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2022₹0.11 Cr
Mar 2023₹1.06 Cr
Mar 2024₹2.43 Cr
Mar 2025₹3.85 Cr
Mar 2026₹3.87 Cr

Half-yearly Results

₹ Cr
544445 half-yearly results, ₹ crore
Particulars Sep 2024Mar 2025Sep 2025Mar 2026
Sales
15.97
9.07
15.42
10.05
Expenses
13.71
5.89
13.19
12.85
Operating Profit
2.26
3.18
2.23
−2.8
OPM %
14.15%
35.06%
14.46%
−27.86%
Other Income
0.64
−0.07
−1.86
4.63
Interest
0.42
0.53
0.28
0.36
Depreciation
0.02
0.02
0.07
0.25
PBT
2.46
2.56
0.02
1.22
Tax %
22.76%
23.44%
−50%
59.84%
Net Profit
1.9
1.95
0.03
0.48
EPS (₹)
3.02
3.11
0.04
0.56

Profit & Loss

₹ Cr
544445 profit and loss, annual, ₹ crore
Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
9.6
6.54
16.03
25.04
25.47
Expenses
9.96
5.02
12.21
19.6
25.99
Operating Profit
−0.36
1.52
3.82
5.44
−0.52
OPM %
−3.75%
23.24%
23.83%
21.73%
−2.04%
Other Income
0.96
0.65
0.25
0.57
6.07
Interest
0.43
0.72
0.76
0.95
0.63
Depreciation
0.01
0.04
0.06
0.04
0.32
PBT
0.16
1.41
3.25
5.02
4.6
Tax %
31.25%
25.53%
25.23%
23.11%
15.87%
Net Profit
0.11
1.06
2.43
3.85
3.87
EPS (₹)
0.2
1.89
3.86
6.14
4.55
Div. Payout %
0%
0%
0%
0%
0%

Balance Sheet

₹ Cr
544445 balance sheet, annual, ₹ crore
Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.7
0.7
0.78
6.27
8.51
Reserves
0.23
1.29
6.4
4.76
30.35
Borrowings
3.31
5.24
6.82
7.26
5.1
Other Liabilities
5.25
6.46
6.7
9.83
7.69
Total Liabilities
9.49
13.69
20.7
28.12
51.65
Fixed Assets
0.92
1.13
0.97
0.96
10.69
CWIP
0
0
0
0
0
Investments
0
0
0
0
0
Other Assets
8.57
12.56
19.73
27.16
40.96
Total Assets
9.49
13.69
20.7
28.12
51.65

Cash Flow

₹ Cr
544445 cash flow, annual, ₹ crore
Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−1.19
−0.32
−3.97
−0.03
−10.18
Investing
0
−0.91
−0.01
0.73
−9.91
Financing
1.29
1.21
3.86
−0.51
21.18
Net Cash Flow
0.1
−0.01
−0.12
0.19
1.09
Free Cash Flow
−1.19
−0.57
−3.98
0.68
−20.24
CFO/EBITDA
322
−20
−92
0
1,500

Ratios

544445 financial ratios, annual
Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
243
481
381
358
524
Inventory Days
27.24
204
53.91
18.59
16.14
Days Payable
247
755
218
157
121
Cash Conversion Cycle
23.79
−69.7
217
220
419
Working Capital Days
−12.17
43.53
163
177
434
ROCE %
—
37.14%
37.78%
36.61%
16.96%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Asston Pharmaceuticals insights

58 extracted metrics across FY22–FY26.

Shareholding Pattern

As of Sep 2026

  • Public 49.92%
  • Promoters 39.48%
  • Others 10.59%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Asston Pharmaceuticals

What does Asston Pharmaceuticals Ltd do?
Incorporated in 2019, Asston Pharmaceuticals Ltd is in the business of manufacturing pharmaceutical products.
Where is Asston Pharmaceuticals Ltd (APL) listed?
Asston Pharmaceuticals Ltd trades under code 544445 on the BSE.
Which sector does Asston Pharmaceuticals Ltd belong to?
Asston Pharmaceuticals Ltd is classified under the Capital Goods sector, in the Other Electrical Equipment industry.
What is the 52-week high and low of Asston Pharmaceuticals Ltd?
Over the last 52 weeks Asston Pharmaceuticals Ltd has traded between ₹60 and ₹153.4 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Asston Pharmaceuticals Ltd?
Asston Pharmaceuticals Ltd reported a return on equity of 15.70%. Its debt-to-equity ratio is 0.13.

Company Information

Incorporated in 2019, Asston Pharmaceuticals Ltd is in the business of manufacturing pharmaceutical products.

Website asstonpharmaceuticals.com
Listed 16 Jul 2025
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/544445.md for Asston Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month